| NCT ID | NCT01973881 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Michigan Rogel Cancer Center |
| Condition | Myelofibrosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 192 participants |
| Start Date | 2014-12-22 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 192 participants in total. It began in 2014-12-22 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is for the development and validation of functional magnetic resonance imaging (MRI) parameters as biomarkers for analyzing extent of disease and quantifying response to treatment in patients with myelofibrosis.
Eligibility Criteria
Inclusion Criteria: 1. Male /female subjects over the age of 18 2. Diagnosis of primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis. 3. No contraindications to MRI 4. Able to undergo MRI without anesthesia \- Exclusion Criteria: 1. Patients with pacemakers or other implanted magnetic devices that may malfunction or move because of the strong magnetic field inside the MRI room and scanner. 2. Any prior adverse event associated with MRI that is not related to injection of contrast agents or other medicines. \-
Contact & Investigator
Gary Luker, M.D.
PRINCIPAL INVESTIGATOR
University of Michigan Hospital
Frequently Asked Questions
Who can join the NCT01973881 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Myelofibrosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT01973881 currently recruiting?
Yes, NCT01973881 is actively recruiting participants. Contact the research team at gluker@umich.edu for enrollment information.
Where is the NCT01973881 trial being conducted?
This trial is being conducted at Ann Arbor, United States.
Who is sponsoring the NCT01973881 clinical trial?
NCT01973881 is sponsored by University of Michigan Rogel Cancer Center. The principal investigator is Gary Luker, M.D. at University of Michigan Hospital. The trial plans to enroll 192 participants.